Please use this identifier to cite or link to this item:
Title: Combined chondroitin sulfate and glucosamine for painful knee osteoarthritis: a multicentre, randomised, double-blind, non-inferiority trial versus celecoxib.
Authors: Hochberg, Marc C
Martel-Pelletier, Johanne
Monfort, Jordi
Möller, Ingrid
Castillo, Juan Ramón
Arden, Nigel
Berenbaum, Francis
Blanco, Francisco J
Conaghan, Philip G
Doménech, Gema
Henrotin, Yves
Pap, Thomas
Richette, Pascal
Sawitzke, Allen
du Souich, Patrick
Pelletier, Jean-Pierre
MOVES Investigation Group
Keywords: Analgesics;NSAIDs;Osteoarthritis
metadata.dc.subject.mesh: Aged
Chondroitin Sulfates
Cyclooxygenase 2 Inhibitors
Double-Blind Method
Drug Combinations
Middle Aged
Musculoskeletal Pain
Osteoarthritis, Knee
Pain Measurement
Quality of Life
Treatment Outcome
Issue Date: 14-Jan-2015
Abstract: To compare the efficacy and safety of chondroitin sulfate plus glucosamine hydrochloride (CS+GH) versus celecoxib in patients with knee osteoarthritis and severe pain. Double-blind Multicentre Osteoarthritis interVEntion trial with SYSADOA (MOVES) conducted in France, Germany, Poland and Spain evaluating treatment with CS+GH versus celecoxib in 606 patients with Kellgren and Lawrence grades 2-3 knee osteoarthritis and moderate-to-severe pain (Western Ontario and McMaster osteoarthritis index (WOMAC) score ≥301; 0-500 scale). Patients were randomised to receive 400 mg CS plus 500 mg GH three times a day or 200 mg celecoxib every day for 6 months. The primary outcome was the mean decrease in WOMAC pain from baseline to 6 months. Secondary outcomes included WOMAC function and stiffness, visual analogue scale for pain, presence of joint swelling/effusion, rescue medication consumption, Outcome Measures in Rheumatology Clinical Trials and Osteoarthritis Research Society International (OMERACT-OARSI) criteria and EuroQoL-5D. The adjusted mean change (95% CI) in WOMAC pain was -185.7 (-200.3 to -171.1) (50.1% decrease) with CS+GH and -186.8 (-201.7 to -171.9) (50.2% decrease) with celecoxib, meeting the non-inferiority margin of -40: -1.11 (-22.0 to 19.8; p=0.92). All sensitivity analyses were consistent with that result. At 6 months, 79.7% of patients in the combination group and 79.2% in the celecoxib group fulfilled OMERACT-OARSI criteria. Both groups elicited a reduction >50% in the presence of joint swelling; a similar reduction was seen for effusion. No differences were observed for the other secondary outcomes. Adverse events were low and similarly distributed between groups. CS+GH has comparable efficacy to celecoxib in reducing pain, stiffness, functional limitation and joint swelling/effusion after 6 months in patients with painful knee osteoarthritis, with a good safety profile. NCT01425853.
metadata.dc.identifier.doi: 10.1136/annrheumdis-2014-206792
Appears in Collections:Producción 2020

Files in This Item:
File SizeFormat 
PMC4717399.pdf1,64 MBAdobe PDFView/Open

This item is protected by original copyright

This item is licensed under a Creative Commons License Creative Commons